We use cookies for a better user experience. Read our Privacy Policy

I Agree

Systemic Inflammatory Response Syndrome Treatment Market

Systemic Inflammatory Response Syndrome Treatment Market (Indication: Meningitis, Urinary Tract Infection (UTI), Pneumonia, Hemorrhage, Autoimmune Diseases, Others; End User: Hospital & Ambulatory Surgical Centers, Specialty Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Public & Private Investments to Foster Growth of Systemic Inflammatory Response Syndrome Treatment Market

The systemic inflammatory response syndrome treatment market is anticipated to grow from ~US$ 9.8 Bn in 2019 to ~US$ 17.8 Bn by 2027, and this healthy growth is attributable to government initiatives taken towards reducing the mortality rate of patients diagnosed with sepsis. Advancements in SIRS therapeutics are further brought in due to investment firms established in developed countries, who fund numerous clinical development programs that possess the capability of formulating effective drugs.

According to the World Health Organization, 7/100 hospitalized patients are highly susceptible to infections, which can cause sepsis. The patient-susceptibility rate in developing countries exceeds even this seven-one-hundred ratio, which signifies profitable opportunities for the systemic inflammatory response syndrome treatment market, as consumers tend to gain financial lucidity along with health consciousness.

systemic inflammatory response syndrome treatment market infographic

Request a sample to get extensive insights into the Systemic Inflammatory Response Syndrome Treatment Market

Popularity of SIRS Treatment to Remain High for Treatment of Urinary Tract Infection

The TMR study finds that, revenue from the treatment of urinary tract infection will increase at a CAGR of ~8%, as dehydration, menopause, high consumption of birth control pills, and frequent involvement in sexual activities are leading causes of UTI. According to medical studies, a female’s body has a shorter urethra than a male’s body, which shortens the distance for bacteria to reach the bladder. This makes women more prone to UTI infections as compared to men, and the participation of women in availing SIRS treatment is also high. However, infections caused by unhygienic conditions that lead to the prevalence of autoimmune diseases are likely to hold significant value in the systemic inflammatory response syndrome treatment market during the forecast period.

To understand how our report can bring difference to your business strategy, Ask for a brochure 

Introduction of Effective Therapies and Drugs to Catalyze Market Growth

As concerns regarding the gravity of sepsis increase, market players operate within the range of innovation to develop effective drugs and therapeutics. Among other therapies, CytoSorb®, a specific extracorporeal cytokine adsorber, is emerging as an effective therapy to reduce inflammation and control the failure of vital organs, such as the lungs, kidneys, heart, and brain. Also, as demand for the initial-stage diagnosis of sepsis becomes more prominent, biomarkers were introduced for early detection, treatment, and disposition of the condition.

Besides therapies, ample efforts backed by central and private funding are leading to the development of numerous pipeline drugs. For instance,

Adrenomed AG introduced Adrecizmab, which is deemed effective for the treatment of septic shock. The drug also holds efficiency in preventing vascular damage and keeping intact ideal vascular functions. Led by efficiency, therapeutics and pipeline drugs are projected to uphold demand in the systemic inflammatory response syndrome treatment market.

Since developed countries remain at the forefront for the development of advanced therapies and drugs, given their sound technical knowledge, partnerships with players in developing countries are seen as a strategic move to gain a reciprocal advantage in the SIRS market. For instance, CytoSorbents Corporation collaborated with Biocon Ltd. to create a huge market for the sales of CytoSorb in overseas territories.

systemic inflammatory response syndrome treatment market segmentation

Stuck in a neck-to-neck competition with other brands? Request a custom report on “Systemic Inflammatory Response Syndrome Treatment Market”

Analysts’ View

Authors of the report infer that, the growth of the systemic inflammatory response syndrome treatment market will be upheld by the technology-intensive approach taken by manufacturers toward the development of sepsis treatment. Extracorporeal blood purification techniques for immunomodulation are gaining momentum in the SIRS treatment market as a potential therapy, while biomarkers and antibody-modified conduits are growing in importance as effective therapeutics.

Leading on the technological scale, North America is anticipated to remain a key investor in the systemic inflammatory response syndrome treatment market. Also, well-established infrastructure, coupled with magnified focus on the sterility of operation units in the healthcare sector of the region, further complements market growth. However, increasing medical tourism and substantial improvements in the healthcare quality of developing countries in Asia Pacific will bring profitable deals for players in the SIRS market.

  • According to Transparency Market Research’s latest market report on the systemic inflammatory response syndrome treatment market for the historical period of 2017 - 2018 and forecast period of 2019 - 2027, rise in the prevalence of systemic inflammatory response syndrome (SIRS) and increase in knowledge about SIRS among healthcare professionals boosts the growth of the global systemic inflammatory response syndrome treatment market.
  • The global systemic inflammatory response syndrome treatment market was valued at ~US$ 9.3 Bn in the year 2018, and is expected to expand at a CAGR of ~8% from 2019 to 2027, to reach a value of ~US$ 17.8 Bn by 2027. 

Rise in Prevalence of SIRS: A Key Driver

  • Systemic inflammatory response syndrome SIRS is one of the major criteria for determining post-surgical complications and end-organ dysfunction. Development of the syndrome is related to long hospital stay, high incidence of multiple organ dysfunction, and increased morbidity.
  • SIRS is among the common post-operative complications in cardiac surgery, leading to organ dysfunction or even death. The prevalence of SIRS among pediatric patients is expected to increase in the near future. An article published by the University of Colorado School of Medicine stated that, out of 56,210 visitors to emergency departments during a 1-year study period, 40,356 pediatric patients met inclusion criteria. Among the included study population, patients with SIRS vital signs accounted for 92.8% of all the visits with fever >38.5°C.
  • An article published by the U.S. National Library of Medicine National Institutes of Health indicated that, out of 372,844,465 visits to the emergency department from 2007 to 2010, an estimated 17.8% ED visitors had SIRS, i.e., 16.6 million adult ED visits with SIRS per year. This retrospective study was conducted as a part of the National Hospital Ambulatory Medical Care Survey (NHAMCS) for four years. The study concluded that SIRS is quite common among visitors to the ED.
  • An article published by the American Academy of Neurology stated that, of the 780 patients with ICH, 21.8% developed non-infectious SIRS and 37.3% developed sepsis during hospitalization.
  • Therefore, steady rise in the prevalence of SIRS is likely to drive the global systemic inflammatory response syndrome treatment market during the forecast period. 

Systemic Inflammatory Response Syndrome Treatment Market: Novel Treatment Approaches

  • Cytokine Adsorption: Cytokine adsorption is one of the promising removal technologies for SIRS. Animal and human studies suggest both, pro- and anti-inflammatory cytokines interact in a complex manner and influence the immune system causing multiple end-organ effects. Cytokine adsorption therapy offers a prospective solution to improve outcomes following SIRS.
  • Biomarkers: Biomarkers have the potential to improve ED-based diagnosis, treatment, and disposition of SIRS patients. Articles published in a number of journals have highlighted the role of biomarkers in SIRS, and over 100 clinical trials are currently enrolling patients for biomarker testing in sepsis. Currently, there are no biomarkers universally accepted for diagnosis and treatment.

Limited Availability of Therapeutics for SIRS Hampers Market

  • Currently, no effective drug for the treatment of SIRS is available in the market. In June 2002, Ono Pharmaceutical Co. Ltd. launched Elaspol 100 for Injection, the world's first drug for acute lung injury associated with SIRS.
  • However, the net sales of the drug declined from US$ 33.3 Mn in 2013 to US$ 11.4 Mn in 2015. Therefore, there is a need to develop new treatment options for SIRS. Moreover, in May 2003, Ono Pharmaceuticals Ltd. announced the termination of exclusive license agreement on Sivelestat (Elaspol 100 for Injection) with Eli Lilly and Company.

Systemic Inflammatory Response Syndrome Treatment Market: Competitive Landscape

  • This report profiles the major players in the global systemic inflammatory response syndrome treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.
  • Prominent players operating in the global SIRS treatment market include -
    • CytoSorbents Corporation
    • RegeneRx Biopharmaceuticals, Inc.
    • Endacea, Inc.
    • Adrenomed AG
    • GlaxoSmithKline plc
    • Asahi Kasei Corporation
    • Cardinal Health
    • Smith & Nephew plc
    • ConvaTec, Inc.
    • AstraZeneca
    • Orion Corporation
    • CHIESI Farmaceutici S.p.A.
    • Mylan N.V.

Systemic Inflammatory Response Syndrome Treatment Market: Key Developments

Key players in the global systemic inflammatory response syndrome treatment market are engaged in the development of new products, mergers & acquisitions, collaborations, and integration. These strategies by industry players are likely to fuel the growth of the systemic inflammatory response syndrome treatment market. Some of the growth strategies adopted by the players are:

  • On March 5, 2019, CytoSorbents Corporation announced the expansion of the direct sales of CytoSorb for all applications to Poland and the Netherlands, and critical care applications to Sweden, Denmark, and Norway. Moreover, the company established CytoSorbents Poland Sp. z.o.o., a wholly-owned subsidiary of CytoSorbents Europe GmbH.
  • In May 2018, approved uses of CytoSorb in the EU were expanded to include removal of bilirubin in liver disease and removal of myoglobin in trauma.
  • In March 2016, CytoSorbents Corporation established CytoSorbents Switzerland GmbH, a wholly-owned subsidiary of CytoSorbents Europe GmbH, to conduct marketing and direct sales in Switzerland.
  • In late June 2012, CytoSorbents Europe GmbH, a European subsidiary of CytoSorbents Corporation was established.
  • In March 2011, CytoSorb, was 'CE marked' in the EU as an extracorporeal cytokine filter indicated for use in clinical situations where cytokines are elevated, allowing for commercial marketing. 

In the global systemic inflammatory response syndrome treatment market report, we have discussed individual strategies, followed by company profiles of manufacturers of SIRS treatment options. The ‘competitive landscape’ section is included in the SIRS treatment report to provide readers with a dashboard view and a company market share analysis of key players operating in the global systemic inflammatory response syndrome treatment market.

Systemic Inflammatory Response Syndrome Treatment Market – Segmentation

Indication

Meningitis

Urinary Tract Infection (UTI)

Pneumonia

Hemorrhage

Autoimmune Diseases

Others

End User

Hospital & Ambulatory Surgical Centers

Specialty Clinics

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Systemic Inflammatory Response Syndrome Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of systemic inflammatory response syndrome treatment market?

Systemic inflammatory response syndrome treatment market is expected to reach to ~US$ 17.8 Bn by 2027

What is the anticipated CAGR of the systemic inflammatory response syndrome treatment market in the forecast period?

Systemic inflammatory response syndrome treatment market is expected to expand at a CAGR of ~8% from 2019 to 2027

What are the key driving factors for the growth of the systemic inflammatory response syndrome treatment market?

Systemic inflammatory response syndrome treatment market is driven rise in the prevalence of systemic inflammatory response syndrome (SIRS)

Which region is expected to project the highest market share in the global systemic inflammatory response syndrome treatment market?

North America accounted for a major share of the global systemic inflammatory response syndrome treatment market

Who are the key players in the systemic inflammatory response syndrome treatment market?

Key players in the global SIRS treatment market include CytoSorbents Corporation, RegeneRx Biopharmaceuticals, Inc., Endacea, Inc., Adrenomed AG, GlaxoSmithKline plc

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Systemic Inflammatory Response Syndrome Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Indication Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Market Outlook

    5.1. Technological Advancements

    5.2. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc.)

    5.3. Regulatory Scenario, by Region/Country

    5.4. Pipeline Analysis

    5.5. Key product/brand Analysis

6. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by Indication

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Indication, 2017–2027 

        6.3.1. Meningitis

        6.3.2. Urinary Tract Infection (UTI)

        6.3.3. Pneumonia

        6.3.4. Hemorrhage

        6.3.5. Autoimmune Diseases

        6.3.6. Others

    6.4. Market Attractiveness, by Indication

7. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by End-user 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by End-user, 2017–2027 

        7.3.1. Hospital & Ambulatory Surgical Centers

        7.3.2. Specialty Clinics

        7.3.3. Others

    7.4. Market Attractiveness, by End-user 

8. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Market Attractiveness, by Country/Region

9. North America Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Indication, 2017–2027 

        9.2.1. Meningitis

        9.2.2. Urinary Tract Infection (UTI)

        9.2.3. Pneumonia

        9.2.4. Hemorrhage

        9.2.5. Autoimmune Diseases

        9.2.6. Others

    9.3. Market Value Forecast, by End-user, 2017–2027 

        9.3.1. Hospital & Ambulatory Surgical Centers

        9.3.2. Specialty Clinics

        9.3.3. Others

    9.4. Market Value Forecast, by Country, 2017–2027 

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis 

        9.5.1. By Indication 

        9.5.2. By End-user 

        9.5.3. By Country

10. Europe Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Indication, 2017–2027 

        10.2.1. Meningitis

        10.2.2. Urinary Tract Infection (UTI)

        10.2.3. Pneumonia

        10.2.4. Hemorrhage

        10.2.5. Autoimmune Diseases

        10.2.6. Others

    10.3. Market Value Forecast, by End-user, 2017–2027 

        10.3.1. Hospital & Ambulatory Surgical Centers

        10.3.2. Specialty Clinics

        10.3.3. Others

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2027 

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Russia

        10.4.7. Rest of Europe

    10.5. Market Attractiveness Analysis 

        10.5.1. By Indication 

        10.5.2. By End-user 

        10.5.3. By Country/Sub-region

11. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Indication, 2017–2027 

        11.2.1. Meningitis

        11.2.2. Urinary Tract Infection (UTI)

        11.2.3. Pneumonia

        11.2.4. Hemorrhage

        11.2.5. Autoimmune Diseases

        11.2.6. Others

    11.3. Market Value Forecast, by End-user, 2017–2027 

        11.3.1. Hospital & Ambulatory Surgical Centers

        11.3.2. Specialty Clinics

        11.3.3. Others

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2027 

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis 

        11.5.1. By Indication 

        11.5.2. By End-user 

        11.5.3. By Country/Sub-region

12. Latin America Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Indication, 2017–2027 

        12.2.1. Meningitis

        12.2.2. Urinary Tract Infection (UTI)

        12.2.3. Pneumonia

        12.2.4. Hemorrhage

        12.2.5. Autoimmune Diseases

        12.2.6. Others

    12.3. Market Value Forecast, by End-user, 2017–2027 

        12.3.1. Hospital & Ambulatory Surgical Centers

        12.3.2. Specialty Clinics

        12.3.3. Others

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2027 

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis 

        12.5.1. By Indication 

        12.5.2. By End-user 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Indication, 2017–2027 

        13.2.1. Meningitis

        13.2.2. Urinary Tract Infection (UTI)

        13.2.3. Pneumonia

        13.2.4. Hemorrhage

        13.2.5. Autoimmune Diseases

        13.2.6. Others

    13.3. Market Value Forecast, by End-user, 2017–2027 

        13.3.1. Hospital & Ambulatory Surgical Centers

        13.3.2. Specialty Clinics

        13.3.3. Others

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2027 

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Israel

        13.4.4. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis 

        13.5.1. By Indication 

        13.5.2. By End-user 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (By Tier and Size of companies)

    14.2. Market Share Analysis, by Company, 2018

    14.3. Company Profiles

        14.3.1. CytoSorbents Corporation

            14.3.1.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.1.2. Financials

            14.3.1.3. Recent Developments

            14.3.1.4. Strategy

        14.3.2. RegeneRx Biopharmaceuticals, Inc.

            14.3.2.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.2.2. Financials

            14.3.2.3. Recent Developments

            14.3.2.4. Strategy

        14.3.3. Endacea, Inc.

            14.3.3.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.3.2. Strategy

        14.3.4. Adrenomed AG

            14.3.4.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.4.2. Recent Developments

            14.3.4.3. Strategy

        14.3.5. GlaxoSmithKline plc

            14.3.5.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.5.2. Financials

            14.3.5.3. Recent Developments

            14.3.5.4. Strategy

        14.3.6. Asahi Kasei Corporation

            14.3.6.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.6.2. Financials

            14.3.6.3. Recent Developments

            14.3.6.4. Strategy

        14.3.7. Cardinal Health

            14.3.7.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.7.2. Financials

            14.3.7.3. Recent Developments

            14.3.7.4. Strategy

        14.3.8. Smith & Nephew plc

            14.3.8.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.8.2. Financials

            14.3.8.3. Recent Developments

            14.3.8.4. Strategy

        14.3.9. ConvaTec, Inc.

            14.3.9.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.9.2. Financials

            14.3.9.3. Recent Developments

            14.3.9.4. Strategy

        14.3.10. AstraZeneca

            14.3.10.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.10.2. Financials

            14.3.10.3. Recent Developments

            14.3.10.4. Strategy

        14.3.11. Orion Corporation

            14.3.11.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.11.2. Financials

            14.3.11.3. Recent Developments

            14.3.11.4. Strategy

        14.3.12. CHIESI Farmaceutici S.p.A.

            14.3.12.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.12.2. Financials

            14.3.12.3. Recent Developments

            14.3.12.4. Strategy

        14.3.13. Mylan N.V.

            14.3.13.1. Overview (HQ, Employee Strength, Business Segments)

            14.3.13.2. Financials

            14.3.13.3. Recent Developments

            14.3.13.4. Strategy

*Note: Financial details of companies that do not report this information in public domain might not have been captured

List of Tables

Table 1Global Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 2 Global Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 3 Global Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 4 North America Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 5 North America Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 6 North America Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 7 Europe Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 8 Europe Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 9 Europe Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 10 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–202

Table 11 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 12 Latin America Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Mn) Forecast, by Indication, 2017–2027

Table 13 Latin America Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027

Table 14 Latin America Systemic Inflammatory Response Syndrome Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 15 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027

Table 16 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

Table 17 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 18 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

List of Figures

Figure 1 Global Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn), by Indication, 2018

Figure 2 Global Systemic Inflammatory Response Syndrome Treatment Market Share, Top Trends, by Indication, 2018

Figure 3 Global Systemic Inflammatory Response Syndrome Treatment Market Share, by Region, 2018

Figure 4 Global Systemic Inflammatory Response Syndrome Treatment Market Share Analysis, by Region

Figure 5 Porter’s Five Forces Analysis 

Figure 6 Global Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) and Forecast, 2019–2027

Figure 7 Global Systemic Inflammatory Response Syndrome Treatment Market Value Share, by Indication, 2018

Figure 8 Global Systemic Inflammatory Response Syndrome Treatment Market Value Share, by End-user, 2018

Figure 9 Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication, 2018 and 2027

Figure 10 Global Systemic Inflammatory Response Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), by Meningitis, 2017–2027

Figure 11 Global Systemic Inflammatory Response Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), by Urinary Tract Infection (UTI), 2017–2027

Figure 12 Global Systemic Inflammatory Response Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), by Pneumonia, 2017–2027

Figure 13 Global Systemic Inflammatory Response Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemorrhage, 2017–2027

Figure 14 Global Systemic Inflammatory Response Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), by Autoimmune Diseases, 2017–2027

Figure 15 Global Systemic Inflammatory Response Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 16 Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Indication, 2019–2027

Figure 17 Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 18 Global Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), Hospitals & Ambulatory Surgical Centers, 2017–2027

Figure 19 Global Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2017–2027

Figure 20 Global Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 21 Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by End-user, 2019–2027

Figure 22 Global Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Region, 2018 and 2027

Figure 23 Global Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Region, 2019–2027

Figure 24 North America Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 25 North America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Country, 2019–2027

Figure 26 North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication, 2018 and 2027

Figure 27 North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 28 North America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country, 2018 and 2027

Figure 29 North America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Indication, 2019–2027

Figure 30 North America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by End-user, 2019–2027

Figure 31 Europe Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 32 Europe Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 33 Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication, 2018 and 2027

Figure 34 Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 35 Europe Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 36 Europe Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Indication, 2019–2027

Figure 37 Europe Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by End-user, 2019–2027

Figure 38 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 39 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2027

Figure 40 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication, 2018 and 2027

Figure 41 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 42 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 43 Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Indication, 2018-2027

Figure 44 Asia Pacific Europe Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by End-user, 2019–2027

Figure 45 Latin America Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 46 Latin America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 47 Latin America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication, 2018 and 2027

Figure 48 Latin America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 49 Latin America Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 50 Latin America Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Indication, 2019–2027

Figure 51 Latin America Europe Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by End-user, 2019–2027

Figure 52 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 53 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2027

Figure 54 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Indication, 2018 and 2027

Figure 55 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by End-user, 2018 and 2027

Figure 56 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 57 Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by Indication, 2019–2027

Figure 58 Middle East & Africa Europe Systemic Inflammatory Response Syndrome Treatment Market Attractiveness Analysis, by End-user, 2019–2027

Figure 59 CytoSorbents Corporation R&D Expense (US$ Mn), 2016–2018

Figure 60 CytoSorbents Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure 61 CytoSorbents Corporation Breakdown of Net Sales, by Region, 2018

Figure 62 RegeneRx Biopharmaceuticals, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2018

Figure 63 RegeneRx Biopharmaceuticals, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2018

Figure 64 GlaxoSmithKline plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 65 GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2018

Figure 66 GlaxoSmithKline plc Breakdown of Net Sales (%), by Geography, 2018

Figure 67 GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 68 Asahi Kasei Corporation Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2018

Figure 69 Asahi Kasei Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure 70 Asahi Kasei Corporation Breakdown of Net Sales (%), by Business Segment, 2018

Figure 71 Cardinal Health Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2019

Figure 72 Cardinal Health Medical Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017

Figure 73 Smith & Nephew plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure 74 Smith & Nephew plc R&D Expenses (US$ Mn), 2015–2018

Figure 75 Smith & Nephew plc Breakdown of Net Sales (%), by Region, 2018

Figure 76 Smith & Nephew plc Breakdown of Net Sales (%), by Business Segment, Advanced Wound Devices, 2018

Figure 77 ConvaTec, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2018

Figure 78 ConvaTec, Inc. Breakdown of Net Sales (%), by Region, 2018

Figure 79 ConvaTec, Inc. Breakdown of Net Sales (%), by Business Segments, 2018

Figure 80 AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 81 AstraZeneca Breakdown of Net Sales (%), by Region, 2018

Figure 82 AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 83 AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2018

Figure 84 Orion Corporation Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 85 Orion Corporation Breakdown of Net Sales (%), by Geography, 2018

Figure 86 Orion Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 87 Orion Corporation Breakdown of Net Sales (%), by Business Segment, 2018

Figure 88 CHIESI Farmaceutici S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 89 CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Geography, 2018

Figure 90 CHIESI Farmaceutici S.p.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 91 CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Therapeutic Area (Business Segment), 2018

Figure 92 Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 93 Mylan N.V. R&D Expenses (US$ Mn), 2017 and 2018

Figure 94 Mylan N.V. Breakdown of Net Sales, by Geography, 2018

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

739

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved